Evidence map›Paper›PMID 29475139›Full record

ArticleTranslational oncology2018

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.

Md Sazzad Hassan, Niranjan Awasthi, Jun Li, Fiona Williams, Margaret A Schwarz, Roderich E Schwarz, Urs von Holzen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Nanodrugs systems for therapy and diagnosis of esophageal cancer.Frontiers in bioengineering and biotechnology · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Md Sazzad HassanDepartment of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617. Electronic address: hassansa@iu.edu.
Niranjan AwasthiDepartment of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617.
Jun LiDepartment of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN 46556.
Fiona WilliamsDepartment of Biological Sciences, University of Notre Dame, IN 46556.
Margaret A SchwarzHarper Cancer Research Institute, South Bend, IN 46617; Department of Biological Sciences, University of Notre Dame, IN 46556; Department of Pediatrics, Indiana University School of Medicine, South Bend, IN 46617.
Roderich E SchwarzDepartment of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617; Goshen Center for Cancer Care, Goshen, Goshen, IN 46526.
Urs von HolzenDepartment of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617; Goshen Center for Cancer Care, Goshen, Goshen, IN 46526; University of Basel, Basel, Switzerland.
Indiana University South Bend · USUniversity of Notre Dame · USGoshen Health · USMike and Josie Harper Cancer Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.

Identifiers

PMID29475139
PMCPMC5884213
OpenAlexW2791014148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.